Clinical Trial Search

Primary: Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM — 16.7; 15.4; 16.2; 15.6 Millimeters of Mercury (mmHg)

Primary: Number of Participants With Sustained Virological Response Rate — 52; 27 participants — p=0.0060

Primary: Number of Participants Who Developed a Positive Antibody Response (IgG) to Keyhole Limpet Hemocyanin (KLH) Immunization — 2; 2 participants

Primary: Progression Free Survival (PFS) Based on Well-documented and Verifiable Progression Events — 26.3; 23.4 Months — p=>0.05

Primary: 11-point Visual Analog Scale for Pain — 7.1; 7.3 units on a scale

Primary: HSV Shedding Rate in Those Receiving Oral TDF, Vaginal TFV, or Double Placebo — 22.9; 13.8; 21.3; 19.5 percentage of swabs positive (%) — p=0.086

Primary: Wet Sputum Weight — 3.8; 4.6 grams

Primary: Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12 — -0.3941; 3.7285 Percentage — p=<0.0001

Primary: All-cause Hospitalisations — 637; 633 Events

Primary: Need of Exchange Transfusion — 6; 7 participants — p=0.765

Primary: Time-Normalized Area Under Curve (AUC) of Physician Global Assessment (PGA) of Psoriasis Score at Week 52 — 1.64; 1.33 Units on a scale

Primary: Incidence of Biopsy Confirmed Acute Rejection at 12 Months. — 5 participants

Primary: Number of Participants Who Shed Virus — 0 participants

Primary: Time to the First Relapse of AD During the Maintenance Phase — NA; 142.0 Days — p=<0.0001

Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants